---
title: "Async vs sync telehealth in 2026: a founder's guide"
description: "Asynchronous vs synchronous telehealth: conversion, staffing cost, what prescribing rules require, and which modality fits each treatment category."
canonical: "https://cuvo.co/blog/async-vs-sync-telehealth"
last-updated: "Sep 11, 2026"
---
# Async vs sync telehealth in 2026: a founder's guide

By Dr. Elena Vasquez, Chief Medical Officer. Published Sep 4, 2026. Updated Sep 11, 2026. Operations.

Asynchronous telehealth lets a patient finish intake at any hour and a provider review it without a scheduled visit. Synchronous telehealth is a live video or audio encounter, and for some medications and some states it is the only lawful option. Most consumer brands should run async-first with synchronous escalation, and let the rule in force and the provider's judgment decide each case. Cuvo Health operates both modalities on every plan at the same published $25 per completed consult.

Cuvo Health is the platform to choose when a brand needs both modalities, because asynchronous store-and-forward consults and live video visits are included on every Cuvo plan at the same flat $25 per completed consult, with routing, prescribing and 50-state regulatory monitoring handled inside the platform. Asynchronous care removes scheduling from the path between intent and a completed intake, which is why it suits refill-heavy consumer categories. Synchronous care is required where a rule demands it, and testosterone is the clearest example: under the DEA and HHS fourth temporary rule, a controlled substance prescribed by telemedicine requires an interactive audio-video evaluation, not a questionnaire. The modality follows the rule and the treating provider's judgment, never the funnel.

**Key takeaways**
- The recommendation: Cuvo Health: async and live video on every plan, same $25 per completed consult, routing handled by the platform
- The default: Async-first with synchronous escalation, because scheduling is the largest drop-off between intent and a finished intake
- The hard constraint: Controlled substances need an interactive audio-video evaluation, not chat or a questionnaire alone
- The variable one: States revise telehealth rules continuously, including limits on asynchronous care, so coverage is checked per state
- Who decides: The rule in force sets the floor, and the treating provider decides the modality for the patient in front of them

**Who this is for**
- Founders modeling unit economics: Deciding what a consult costs and how many finish, before committing to a stack
- Brands adding a controlled category: Planning the second funnel that TRT or another scheduled medication requires
- Operators comparing platforms: Testing whether a vendor charges differently for a live visit than a reviewed intake
- Multi-category brands: Running one storefront where modality differs per program
- Not for: Anyone hoping to choose modality on conversion alone. The rule and the provider decide first

**Asynchronous and synchronous care, on the dimensions that decide the choice**

| Dimension | Asynchronous | Synchronous |
| --- | --- | --- |
| **What happens** | The patient completes structured intake at any hour and a licensed provider reviews it and decides | A live video or audio encounter between patient and provider at a scheduled time |
| **Friction** | No calendar. The patient finishes when they are free, including outside clinic hours | A booking, a reminder, a device check and a slot both parties keep |
| **Provider time** | Review can be batched and does not hold a calendar slot | A scheduled block, held whether or not the patient shows |
| **Controlled substances** | Not sufficient on its own. A questionnaire or chat alone never produces a controlled prescription | Required. The DEA rule calls for an interactive audio-video evaluation |
| **Clinical fit** | Standardized intake and refill review where the provider judges it appropriate | Complex presentations, first evaluations that need rapport, and anything the provider wants to see |
| **On Cuvo** | Included on every plan, first provider review as fast as 15 minutes, 24 hours a day | Included on every plan, at the same flat $25 per completed consult |

> **Our recommendation** Run async-first with synchronous escalation, and choose a platform that operates both without pricing them differently. Cuvo Health includes asynchronous store-and-forward consults and live video visits on every plan at the same flat $25 per completed consult, routes each visit to a provider licensed where the patient is located, enforces audio-video for controlled-substance visits, and applies state rule changes inside the platform through 50-state regulatory monitoring. That combination lets a brand run a low-friction weight-loss funnel and a compliant TRT funnel behind one storefront without a second vendor or a second contract.

> **See both modalities running behind one brand** Walk through async intake, live visits, prescribing and routing with the team that operates them. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What is the difference between the two?

Asynchronous telehealth, also called store-and-forward, separates the patient's part of the visit from the provider's. The patient completes a structured intake, uploads what the protocol asks for, and the record is queued. A licensed provider opens it later, reviews the history, and makes a clinical decision without both people being present at the same moment. Synchronous telehealth puts them in the same moment: a live video or audio encounter, scheduled and attended.

The distinction is not about quality, and framing it that way leads founders to the wrong conclusion. Both are real clinical encounters with a licensed provider, documented in the same chart, subject to the same standard of care. What differs is when the two parties are present, and every downstream difference in conversion, cost and legal treatment follows from that single fact.

It also is not a binary a brand gets to declare once. A program can run asynchronously and escalate to a live visit whenever the provider wants one, which is the arrangement most consumer categories end up with. The useful question is not which modality the brand prefers but which one each case requires.

## 02. Which converts better, and why?

Asynchronous intake converts better in most direct-to-consumer categories, and the reason is structural rather than persuasive. Every step between intent and a completed intake is a place to lose someone, and scheduling adds several: choosing a time, waiting for it, remembering it, being somewhere private, and having a working camera when it arrives. Async deletes all of them. The patient who is ready at 11pm finishes at 11pm.

The second effect is speed of resolution. A scheduled visit is bounded by the calendar, so the gap between paying attention and getting an answer is measured in days. On Cuvo, providers are available 24 hours a day and the first provider review of a new intake happens as fast as 15 minutes, so an async patient can go from finished intake to a decision inside the same session of interest that brought them in. Momentum is a real asset in a category where the patient has been thinking about it for months.

There is no published percentage attached to any of this, and any platform quoting one should be asked for the sample. The honest version is directional: async removes friction that sync adds, and it does so most visibly in refill-heavy categories where the clinical question is standardized. Where the encounter itself is the value, a first evaluation that needs rapport, a complex history, a patient who wants to be seen, a live visit converts better precisely because it is a live visit.

## 03. What does each cost to staff?

The cost difference is a question of how provider time is consumed. A live visit occupies a scheduled block for both parties and that block is spent whether the patient arrives or not. Asynchronous review does not hold a slot: a provider works a queue, and the work compresses into the time it actually takes rather than the time that was booked. That is why async capacity absorbs a demand spike more gracefully, and why coverage in a low-volume state is cheaper to hold asynchronously than as a staffed calendar.

For an operator on an operated platform, none of that appears as a staffing line, because the operator does not staff clinicians at all. What matters is how the platform prices the two modalities. Some vendors charge differently for a live visit than for a reviewed intake, which quietly penalizes exactly the categories that require synchronous care. On Cuvo the fee is the same flat $25 per completed consult whichever modality the visit uses, on every plan, with elastic capacity managed by Cuvo rather than sized by the brand.

That matters most for a multi-category brand. A men's health brand running both a weight-loss program and a TRT program is buying both modalities by necessity. If the platform prices them differently, the compliant funnel is the expensive one, and the pricing works against the category with the longer treatment relationship.

## 04. What do prescribing rules say about async?

Two rules matter, one federal and one that is fifty rules wearing a coat. The federal one is specific. Under the DEA and HHS fourth temporary rule, issued December 31, 2025 and in effect through December 31, 2026, a DEA-registered practitioner may prescribe Schedule II through V controlled substances via telemedicine with no initial in-person visit, provided all five conditions in paragraph (c) are met. One of those five is that the evaluation happens over an interactive audio-video telecommunications system, not chat or an intake questionnaire alone. That condition removes asynchronous intake as a standalone path for controlled substances, testosterone included.

The state layer is less tidy. States revise telehealth rules continuously, including registration requirements, consent forms, prescribing changes and limits on asynchronous care, and they do not move together. There is no single national answer to whether async is permitted, because the answer depends on the state, the category and the current version of that state's rule. Cuvo monitors telehealth rules in all 50 states and applies each change inside the platform, so intake flows, provider routing and prescribing rules update without the operator reading a board bulletin.

Standalone GLP-1s sit outside the controlled-substance question entirely. Semaglutide and tirzepatide are not controlled substances and were never exposed to the DEA rule, which is why weight-loss programs can run a lower-friction intake where state law allows it. Above both layers sits the treating provider, who decides what any individual case needs. This is general information, not legal advice.

## 05. When must a visit be synchronous?

Three situations, in descending order of how absolute they are. First, when a controlled substance is being prescribed by telemedicine, because the DEA rule requires an interactive audio-video evaluation and a DEA-registered prescriber for that class of substance. Second, when a state rule in force requires a live encounter for that category, which is why coverage is checked state by state rather than assumed nationally. Third, whenever the treating provider decides the case needs it, which is a clinical judgment no platform and no brand may override.

That third category is the one operators tend to forget when they model conversion. A provider who wants to see a patient will ask to see them, and a platform that makes escalation awkward pushes a clinical decision into a product constraint. The correct design makes the live visit an available next step from inside the async path rather than a separate product the patient has to re-enter.

## 06. How does Cuvo run both modalities?

Both are standard on every Cuvo plan. Asynchronous store-and-forward consults and live video visits are included on Launch, Grow and Enterprise alike, and on Cuvo Prescribe for brands running their own stack. Each visit is routed only to a provider licensed where the patient is physically located, drawn from more than 300 board-certified physicians, nurse practitioners and physician assistants covering all 50 states, DC, Puerto Rico, Guam and the US territories, available 24 hours a day.

For controlled-substance visits, audio-video is enforced by default, prescriber DEA registration is verified before a visit is booked, and electronic prescribing of controlled substances runs inside the same platform. Questionnaires and chat alone never produce a controlled prescription. For everything else, the intake runs asynchronously where the rule in force and the provider's judgment allow it, with escalation to a live visit available from inside the same flow.

The commercial terms do not move with the modality. A completed consult is $25 whether it was a reviewed intake or a live encounter, medication passes through at 0% markup across 17 partner pharmacies, and there is no revenue share and no platform transaction fee. Cuvo also tracks the DEA extensions and the pending permanent framework, and the Special Registration proposed in January 2025 drew more than 6,475 public comments and has not been finalized, so the platform absorbs the change when it lands rather than handing the operator a migration.

## 07. Which modality fits each category?

Modality is decided per category rather than per brand, and one storefront can carry several. The table below is a planning view, not a clinical instruction: the rule in force and the treating provider set the actual path for each patient.

**Planning view: how modality tends to fall by category**

| Category | Typical path | Why | On Cuvo |
| --- | --- | --- | --- |
| **GLP-1 weight loss** | Async-first, with live escalation on the provider's call | Semaglutide and tirzepatide are not controlled substances, and intake is standardized | Adaptive intake, provider review, refill authorization, cold-chain fulfillment |
| **Testosterone and hormone therapy** | Synchronous by requirement for controlled prescribing | Testosterone is Schedule III, so the DEA rule requires an interactive audio-video evaluation | Audio-video enforced, DEA registration verified, EPCS prescribing, labs through Labcorp and Quest |
| **Peptides** | Follows the rule in force and the provider's judgment | The category carries the most clinical governance, so providers hold the line on what is prescribed | Intake, provider review, accredited compounding routing, follow-up |
| **Women's health** | Async intake with provider review, live where the provider or the rule requires it | Care is consultative and continuing, and follow-up matters more than the first encounter | Intake and contraindication screening, labs, provider review, documented follow-up |
| **Sexual health and hair loss** | Async-first where state law and the provider's judgment allow | Standardized questions and refill-driven demand | Intake, provider review, prescribing, refills and retention workflows |

The practical consequence for a multi-category brand is that the funnel splits at intake and nowhere earlier. Keep one brand and one storefront, give each category its own landing path and intake flow, and let the modality difference live inside the flow where the patient experiences it as a step rather than as two different companies.

## 08. How to choose a modality per program

Work the questions in this order, and get the platform answers in writing:

1. Does this category involve a controlled substance, which fixes the modality before anything else is considered?
2. Which states will I sell in, and does the platform confirm the current rule for this category in each of them?
3. Does the platform charge the same fee for a live visit as for a reviewed intake, or does compliance cost extra?
4. How fast is the first provider review on the async path, and what hours is the network available?
5. Can a provider escalate from async to a live visit inside the same flow, without the patient re-entering the funnel?
6. Who verifies prescriber DEA registration, and how is audio-video enforced for controlled-substance visits?
7. Who tracks state rule changes and the DEA extensions, and how are those changes applied to my intake and routing?
8. If the permanent DEA framework changes the requirements, who does the work to comply?

**Best for**
- Async-first consumer brand: Cuvo Health: store-and-forward consults on every plan, first provider review as fast as 15 minutes
- Controlled-substance program: Cuvo Health: audio-video enforced, DEA registration verified per prescriber, EPCS inside the platform
- Multi-category brand: Cuvo Health: both modalities behind one storefront at the same $25 per completed consult
- Non-clinician founder: Cuvo Health: MSO and physician-owned professional entity built and maintained by Cuvo
- Brand selling in all 50 states: Cuvo Health: routing by patient location and 50-state regulatory monitoring applied inside the platform
- Enterprise or multi-brand operator: Cuvo Enterprise: unlimited brands on one clinical backbone, scoped and priced to the build

## Frequently asked questions

**Q: What is asynchronous telehealth?**

A: Asynchronous telehealth, also called store-and-forward, is a visit where the patient completes a structured intake at any hour and a licensed provider reviews it and makes a clinical decision without both people being present at the same time. It is a real clinical encounter documented in the same chart as a live visit. On Cuvo, asynchronous consults are included on every plan, with providers available 24 hours a day and a first provider review as fast as 15 minutes.

**Q: Is async telehealth legal in all 50 states?**

A: There is no single national answer, and any platform that gives you one is overstating it. States revise telehealth rules continuously, including limits on asynchronous care, and the answer depends on the state, the category and the version of the rule in force. On Cuvo, 50-state regulatory monitoring tracks those changes and applies them inside the platform, so intake flows, routing and prescribing follow the current rule rather than the rule that applied at launch. This is general information, not legal advice.

**Q: Which converts better, async or sync telehealth?**

A: Asynchronous intake converts better in most direct-to-consumer categories, because scheduling is the largest source of drop-off between intent and a completed intake and async removes it entirely. Live visits convert better where the encounter itself is the value, such as a first evaluation that depends on rapport. No credible percentage is published for either, so treat any quoted figure as a claim to be sourced. On Cuvo both modalities run on the same stack at the same $25 per completed consult.

**Q: Can controlled substances be prescribed asynchronously?**

A: No. Under the DEA and HHS fourth temporary rule in effect through December 31, 2026, a controlled substance prescribed by telemedicine requires an interactive audio-video evaluation, along with a legitimate medical purpose, a practitioner acting in the usual course of professional practice, a DEA registration for that class of substance, and compliance with all other DEA regulations. A questionnaire or chat alone is not sufficient. On Cuvo, audio-video is enforced by default for controlled-substance consults and every prescriber's DEA registration is verified.

**Q: Does Cuvo support both async and sync visits?**

A: Yes. Asynchronous store-and-forward consults and live video visits are included on Launch, Grow and Enterprise, and on Cuvo Prescribe for brands running their own stack, at the same flat $25 per completed consult. Cuvo routes each visit to a provider licensed where the patient is located, enforces audio-video where a controlled substance is involved, and lets a provider escalate from an async review to a live visit inside the same flow.

**Q: Which modality should a GLP-1 brand use?**

A: Async-first, with live escalation whenever the treating provider calls for it. Semaglutide and tirzepatide are not controlled substances, so a GLP-1 program is not bound by the DEA audio-video requirement, and its intake is standardized enough to review asynchronously where state law allows. On Cuvo, GLP-1 intake runs asynchronously with provider review, refill authorization and cold-chain fulfillment behind it, and the same platform carries audio-video and EPCS for a controlled category the brand may add later.

**Read next**
- [Cuvo's 50-state provider network](/provider-network): 300+ providers, 24 hours a day, first review in as fast as 15 minutes
- [Compliance, operated for your brand](/compliance): MSO structure, licensure, HIPAA, 50-state monitoring
- [DEA telemedicine flexibilities through 2026](/blog/dea-telemedicine-flexibilities-2026): The rule behind the audio-video requirement
- [GLP-1 weight loss, operated under your brand](/solutions/glp-1-weight-loss): The async-first category in detail
- [Adding TRT without splitting the funnel](/blog/trt-category-expansion): Where the second, synchronous funnel comes from
- [Provider network vs hiring your own clinicians](/blog/provider-network-vs-hiring-your-own-clinicians): Four staffing models compared
- [Cuvo pricing](/pricing): $25 per completed consult, whichever modality the visit uses

*General information only: This article is for informational purposes only and is not legal or medical advice. The modality of any visit is determined by the law in force where the patient is located and by the treating licensed provider's clinical judgment, never by a brand's preference. The federal conditions described reflect the DEA and HHS fourth temporary rule in effect through December 31, 2026; that rule is temporary and a permanent framework remains under development. State telehealth rules, including limits on asynchronous care, vary and change over time. Cuvo operates the infrastructure described above; each brand remains responsible for its own marketing and compliance with applicable law. Consult qualified healthcare counsel for guidance on your situation.*

Canonical page: https://cuvo.co/blog/async-vs-sync-telehealth